UBS raised the firm’s price target on Ecolab (ECL) to $288 from $271 and keeps a Neutral rating on the shares. Better than feared tariff impacts could support downstream firms in the quarter, while commodities are likely to remain under pressure with weaker demand trends, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ECL:
- Merit Medical CEO Fred Lampropoulos to leave role, Martha Aronson to succeed
- Ecolab price target raised to $320 from $285 at Citi
- Ecolab’s Balanced Outlook: Hold Rating Amid Pricing Strategy and Market Challenges
- Ecolab Completes $500 Million Notes Issuance
- Ecolab’s Strategic Growth and Digital Integration Drive Buy Rating